Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc reports news as a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. Coverage centers on Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, including wound dressings, negative pressure wound therapy, cartilage and rotator cuff repair implants, orthopedic reconstruction, trauma and extremities products, and surgical robotics.
Recurring developments include product launches and clinical evidence for ALLEVYN COMPLETE CARE, RENASYS EDGE, CARTIHEAL AGILI-C, REGENETEN, CORI, AETOS and related platforms; conference showcases; distribution agreements; segment performance updates; share buybacks; and governance matters tied to the company’s London-listed shares and NYSE-traded ADRs.
Smith+Nephew (NYSE: SNN) has introduced ASC Solutions, an expanded enterprise strategy for ambulatory surgery centers focused on cost optimization, quality, and outcome performance. The offering aims to connect ASC customers with procedural technologies, clinical expertise, and advanced data and analytics to support growth and operational efficiency.
As part of this strategy, Smith+Nephew is expanding its ASC ONE delivery model into an integrated platform that coordinates development planning, design and construction, financing, IT infrastructure, sterile processing, and clinical enablement through a single point of coordination. According to Smith+Nephew, a network of partners including STERIS, Unity Health Centers, Brasfield & Gorrie, Ghafari, and Hopper Healthcare helps support ASCs across their full lifecycle.
Smith+Nephew (LSE:SN, NYSE:SNN) has commercially launched the LYNX COBLATION Laryngeal Wand, a multi-purpose ENT device designed by laryngologists for airway procedures from the supraglottis to the trachea. The wand combines fine dissection and mass debulking capabilities at low temperatures, aiming to reduce airway fire risk compared to electrocautery or CO₂ laser.
Key design features include a long working length for improved access, 360-degree radial incision capability, a malleable shaft to adapt to patient anatomy, and self-clearing functionality intended to reduce clogging during use. The wand uses Smith+Nephew’s COBLATION ENT Technology, backed by over 20 years of clinical use and more than 240 peer-reviewed publications, for precise soft tissue ablation, resection, coagulation and hemostasis.
Smith+Nephew (NYSE:SNN) reported completion of the first clinical cases using its next-generation CORI◊ XT Handheld Robotics Platform across knee and shoulder arthroplasty. The platform is designed as a single handheld system for partial to revision knee, hip* and shoulder procedures in hospitals and ambulatory surgery centers.
Smith+Nephew (NYSE:SNN) has launched its next generation LEAF Patient Monitoring System in the US, a cloud-hosted, data-driven platform for hospital-acquired pressure injury (HAPI) prevention.
The system uses wearable sensors, EMR integration and real-time turn status to support protocol adherence, reduce HAPI odds by up to 73%, and has delivered up to $1.8M in estimated savings in one critical care facility.
Smith+Nephew (SNN) will launch ALLEVYN COMPLETE CARE foam dressing and RENASYS EDGE negative pressure wound therapy at EWMA, Bremen, May 6-8, 2026.
ALLEVYN COMPLETE CARE features a five-layer design with ExuLOCK, ExuMASK change indicator and ShearDEFENSE. RENASYS EDGE is a lightweight, modular tNPWT pump reporting improved outcomes and an average 88% therapy-session patient compliance.
Smith+Nephew (NYSE:SNN) reported 5-year randomized trial results showing the CARTIHEAL AGILI-C implant delivered higher KOOS scores versus standard care through 60 months with superior pain relief and functional gains. The implant is FDA-approved, commercially available in the US, and received a Category I CPT code effective Jan 1, 2027.
Results were comparable for patients with and without osteoarthritis, and clinicians reported roughly twice the pain reduction versus debridement or microfracture.
Smith+Nephew (NYSE:SNN) reported randomized controlled trial results showing the REGENETEN Bioinductive Implant halved early post‑operative recovery times versus traditional suture anchor repair for partial‑thickness rotator cuff tears. Driving: 2.3 vs 5.1 weeks; office work: 1.7 vs 3.6 weeks; household chores: 3.8 vs 8.4 weeks (all p≤0.009).
The study found better quality of life at 6 weeks and 3 months and high tendon healing rates at 12 months comparable to standard repair; rehabilitation protocols differed between groups.
Smith+Nephew (NYSE:SNN) launched ALLEVYN COMPLETE CARE Foam Dressing on March 10, 2026, a five‑layer dressing designed for wound management and pressure injury prevention. It claims >99% bacterial exclusion, up to 93% mechanical energy absorption, >65% pressure‑injury risk reduction, longer wear times, and staged international rollout beginning in the US with wider European availability in 2026.
Smith+Nephew (NYSE:SNN) will showcase handheld robotics, digital planning and trauma/extremities implants at AAOS 2026 in New Orleans, March 3-6, 2026, Booth #839.
Highlights include the CORI handheld robotics ecosystem and new CORI SHOULDER cases, EVOS plating, TRIGEN MAX tibial nailing, ASC enterprise solutions and new distribution partnerships.
Smith+Nephew (NYSE:SNN) will showcase a comprehensive rotator cuff repair portfolio at AAOS 2026 in New Orleans, featuring the newly acquired Tendon Seam Repair System and the REGENETEN Bioinductive Implant.
Highlights: Tendon Seam has 510(k) clearance (2023); REGENETEN has >250,000 procedures since 2014; AAOS issued a Strong Recommendation for bioinductive implants to lower re-tear rates.